PMC:7499584 / 5373-6156 JSONTXT

{"project":"2_test","denotations":[{"id":"32829416-21676868-45163155","span":{"begin":202,"end":206},"obj":"21676868"},{"id":"32829416-28068312-45163156","span":{"begin":640,"end":644},"obj":"28068312"},{"id":"32829416-29459785-45163157","span":{"begin":657,"end":661},"obj":"29459785"},{"id":"T10245","span":{"begin":202,"end":206},"obj":"21676868"},{"id":"T22273","span":{"begin":640,"end":644},"obj":"28068312"},{"id":"T21921","span":{"begin":657,"end":661},"obj":"29459785"}],"text":"Tunicamycin was employed in antiviral tests and was very effective, but it was considered too toxic by most investigators to be developed as a drug at the concentrations used. However, Banerjee et al. (2011), in cancer treatment, found a safe concentration of a purified tunicamycin and dosage in mice (250 μg/kg oral twice a week for 4 weeks) that inhibited MDA-MB0231 triple negative breast-cancer tumor formation in live mice, without overt toxicity and involved the unfolded protein response. Nanoformulations were effective (Banerjee et al. 2013). Recent articles define the detailed basis for tunicamycin’s activity (Hakulinen et al. 2017; Yoo et al. 2018). Tunicamycins should be tested now for infectivity assays with SARS COV2 alone or in combinations with other inhibitors."}